Read more about the article RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

Continue ReadingRedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59
Read more about the article RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

Continue ReadingRedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59
Read more about the article Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Continue ReadingKadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85
Read more about the article Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

Continue ReadingOramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Read more about the article Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

Continue ReadingOramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Read more about the article Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.

Continue ReadingOramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Read more about the article Enlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.

Enlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.

Enlight Renewable Energy Ltd. is an Israeli company founded in 2008, and is publically traded on the Tel Aviv Stock Exchange. The company specializes in the initiation, development, financing, construction,…

Continue ReadingEnlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.